To determine whether the adoptive transfer of in vitro activated tumor-specific CD4+ T cells could mitigate established metastatic melanoma tumors in vivo, we used T-cell receptor transgenic CD4+ T cells purified from SMARTA (CD45.1+ LCMV GP66–77 I-Ab-specific) or OT-II (CD45.1+ chicken ovalbumin 323–339 I-Ab-specific) transgenic mice. Here, CD4 is linked to neoplasm.